Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description

被引：87

作者：

Cheng, JCH

Wu, JK

Huang, CM

Huang, DY

Cheng, SH

Lin, YM

Jian, JJ

Yang, PS

Chuang, VP

Huang, AT

机构：

[1] Koo Fdn, Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei 112, Taiwan

[2] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei 112, Taiwan

[3] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27706 USA

[4] Koo Fdn, Sun Yat Sen Canc Ctr, Dept Phys Med, Taipei 112, Taiwan

[5] Natl Yang Ming Univ, Sch Med, Inst Radiat Sci, Taipei 112, Taiwan

[6] Koo Fdn, Sun Yat Sen Canc Ctr, Dept Internal Med, Taipei 112, Taiwan

[7] Koo Fdn, Sun Yat Sen Canc Ctr, Dept Surg, Taipei 112, Taiwan

[8] Koo Fdn, Sun Yat Sen Canc Ctr, Dept Diagnost Radiol, Taipei 112, Taiwan

[9] Duke Univ, Med Ctr, Dept Med, Durham, NC 27706 USA

来源：

RADIOTHERAPY AND ONCOLOGY | 2002年 / 63卷 / 01期

关键词：

radiation-induced liver disease; hepatocellular carcinoma; radiotherapy; dosimetry;

D O I：

10.1016/S0167-8140(02)00061-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twelve patients with hepatocellular carcinoma and chronic hepatitis developed radiation-induced liver disease (RILD) after three-dimensional conformal radiotherapy, Six patients died of RILD and six recovered. Mean prescribed dose was 50.6 +/- 4.3 Gy, in a daily fraction of 1.8-2.0 Gy. Commonly used dosimetric parameters, such as fraction volume of normal liver with radiation dose >30 Gy, prediction score, and normal tissue complication probability, failed to differentiate the fatality and clinical types of this complication. Elevated transaminases are more frequently seen than ascites and elevated alkaline phosphamide are seen in patients with RILD. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：41 / 45

页数：5

共 21 条

[1] FITTING OF NORMAL TISSUE TOLERANCE DATA TO AN ANALYTIC-FUNCTION [J].

BURMAN, C ;

KUTCHER, GJ ;

EMAMI, B ;

GOITEIN, M .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01) :123-135

[2]

CHEN MF, 1989, ARCH SURG-CHICAGO, V124, P1025

[3] Local radiotherapy with or without transcatheter arterial chemoemboliziation for patients with unresectable hepatocellular carcinoma [J].

Cheng, JCH ;

Chuang, VP ;

Cheng, SH ;

Huang, AT ;

Lin, YM ;

Cheng, TI ;

Yang, PS ;

You, DL ;

Jian, JJM ;

Tsai, SY ;

Sung, JL ;

Horng, CF .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (02) :435-442

[4] CHEMO-EMBOLIZATION - TRANSCATHETER MANAGEMENT OF NEOPLASMS [J].

CHUANG, VP ;

WALLACE, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 245 (11) :1151-1152

[5]

COOK GG, 1985, AM J MED, V233, P705

[6] Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies [J].

Dawson, LA ;

McGinn, CJ ;

Normolle, D ;

Ten Haken, RK ;

Walker, S ;

Ensminger, W ;

Lawrence, TS .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2210-2218

[7] CALCULATION OF COMPLICATION PROBABILITY FACTORS FOR NON-UNIFORM NORMAL TISSUE IRRADIATION - THE EFFECTIVE VOLUME METHOD [J].

KUTCHER, GJ ;

BURMAN, C .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (06) :1623-1630

[8] HEPATIC TOXICITY RESULTING FROM CANCER-TREATMENT [J].

LAWRENCE, TS ;

ROBERTSON, JM ;

ANSCHER, MS ;

JIRTLE, RL ;

ENSMINGER, WD ;

FAJARDO, LF .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1237-1248

[9] THE USE OF 3-D-DOSE VOLUME ANALYSIS TO PREDICT RADIATION HEPATITIS [J].

LAWRENCE, TS ;

TENHAKEN, RK ;

KESSLER, ML ;

ROBERTSON, JM ;

LYMAN, JT ;

LAVIGNE, ML ;

BROWN, MB ;

DUROSS, DJ ;

ANDREWS, JC ;

ENSMINGER, WD ;

LICHTER, AS .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (04) :781-788

[10]

Lyman J. T., 1985, RADIAT RES, V8, P513

← 1 2 3 →